Title: Bortezomib plus Melphalan and Prednisone for Multiple Myeloma
Abstract:The proteasome inhibitor bortezomib (Velcade) has single-agent activity against relapsed and refractory multiple myeloma, even in patients with...The proteasome inhibitor bortezomib (Velcade) has single-agent activity against relapsed and refractory multiple myeloma, even in patients withRead More
Publication Year: 2008
Publication Date: 2008-08-27
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot